| abstract |
PROLONGED RELEASE LIPID PRECONCENTRATE OF GNRH ANALOGS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME. A pharmaceutical composition is described, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more -OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener that is free of an ionizable group and has a triacyl group of 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin releasing hormone) analogue as a pharmacologically active substance, wherein said lipid preconcentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active GnRH analog substance. |